GLP-1 receptor agonist & SGLT2 inhibitor therapy (type 2 diabetes)
GLP1/SGLT2 · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Guideline-preferred second-line agents in type 2 diabetes chosen for cardiovascular, renal and weight benefits independent of glucose lowering. Selection is driven by comorbidity rather than HbA1c alone.
Red flags
- Euglycaemic diabetic ketoacidosis on SGLT2 inhibitor
- Severe dehydration or acute kidney injury
- Acute pancreatitis or gallbladder disease on GLP-1 agonist
- Fournier gangrene (perineal necrotising infection)
- Persistent severe vomiting (gastroparesis) on GLP-1 agonist
Assessment
Differential diagnosis
- Suboptimal adherence/lifestyle
- Type 1/LADA misclassification
- Steroid-induced hyperglycaemia
- Pancreatic diabetes
Investigations
- HbA1c, weight/BMI and blood pressure
- eGFR and urine ACR
- Cardiovascular risk assessment and history of ASCVD/heart failure
- Review of contraindications (pancreatitis, gastroparesis, recurrent DKA)
Management
- After metformin, prioritise agent by dominant comorbidity
- Choose SGLT2 inhibitor for heart failure or chronic kidney disease
- Choose GLP-1 receptor agonist for established atherosclerotic disease or when weight loss is a priority
- Counsel on injection vs oral route and gastrointestinal side effects for GLP-1 agonists
- Warn about volume depletion, genital mycotic infection and euglycaemic DKA risk with SGLT2 inhibitors
- Advise sick-day rules: withhold SGLT2 inhibitor during acute illness/dehydration/surgery
- Reduce sulfonylurea/insulin to prevent hypoglycaemia when combining
- Monitor HbA1c, weight, renal function and tolerability
- Consider combining the two classes for additive cardiorenal and metabolic benefit
Drugs & doses
Semaglutide SC 0.25 mg weekly titrated to 1-2 mg, or oral 3-14 mg daily
Dulaglutide 0.75-4.5 mg SC weekly
Tirzepatide 2.5 mg SC weekly titrated to 15 mg (GIP/GLP-1)
Dapagliflozin 10 mg or empagliflozin 10-25 mg PO once daily
Disposition
Prescribe and monitor in primary care/diabetes clinic; refer complex cardiorenal patients for combined cardiology/nephrology input and stop agents promptly for red-flag events.
Complications & pitfalls
- Euglycaemic DKA
- Genital and urinary infections
- Volume depletion/AKI
- Gastrointestinal intolerance
- Gallstones and pancreatitis (GLP-1)
Exam pearls
- Choose by comorbidity, not just glucose: SGLT2 for heart failure/CKD, GLP-1 for ASCVD/weight
- Stop SGLT2 inhibitors before major surgery and during significant illness to avoid euglycaemic DKA
- Check ketones even with normal glucose in an unwell SGLT2-treated patient
- Dual-incretin agents (tirzepatide) give the greatest HbA1c and weight reductions
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.